Botulinum toxin type B: a new injectable treatment for cervical dystonia.
Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.
Brashear
A
A
Indiana University School of Medicine, Department of Neurology, 550 University Boulevard, Room 6620, Indianapolis, IN 46202-5250, USA. abrashea@iupui.edu
D000818:Animals; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D002986:Clinical Trials as Topic; D004421:Dystonia / Q000188:drug therapy*; D006801:Humans; D009498:Neurotoxins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D009498:Neurotoxins; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A